Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

NEW ORLEANS -- Patients at a community health center who had type 2 diabetes and a high risk of atherosclerotic ...

More work is needed to understand how to act preemptively on elevated heart failure risk, one researcher says.

Heart failure - treatment ... Sodium-glucose transport protein 2 (SGLT2) inhibitors. In: StatPearls. StatPearls Publishing; 2024. Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a newer class of medications used to treat type 2 diabetes. These ...

This Diabetes Heart Connection Day we explore how management of diabetes and cardiovascular care often go hand in hand.

(Journal of the American College of Cardiology) The SGLT2 inhibitor dapagliflozin ... cardiovascular or kidney disease in a pooled trial analysis. (European Heart Journal) Patients with ...

Regarding both analyses, patients taking GLP-1 or SGLT2 inhibitor medications may face higher risks for mortality or serious heart problems due to existing metabolic disorders or heart disease ...